This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

close

SUSPECT
PULMONARY
FIBROSIS

Patients with suspect pulmonary fibrosis holding their lung scans
Patients with suspect pulmonary fibrosis holding their lung scans

PULMONARY FIBROSIS CAN BE INSIDIOUS AND UNPREDICTABLE.
YOUR VIGILANCE MAKES A DIFFERENCE

 

Worsening of symptoms or decline in lung function measured by PFT can mean that a patient’s
pulmonary fibrosis is progressing1

Monitoring of respiratory deteriorating symptoms such as dyspnoea and cough  in patients with ILDs

Conduct proactive and regular monitoring for any
deterioration in respiratory symptoms such as
dyspnoea and cough2,3

HRCT evaluation at the first suspicion of ILD involvement to help diagnosis.

For at-risk patients, HRCT should be evaluated at the first
suspicion of ILD involvement, if possible at baseline
diagnosis, and repeated upon worsening of either PFT
or respiratory symptoms4,5 

Demonstrate a healthy suspicion

Identifying pulmonary fibrosis in patients as early as possible may help to improve their burden of disease, slow decline in daily functioning and quality of life, and reduce the risk of early mortality6,7

DOWNLOAD RESOURCES TO FIND OUT MORE ABOUT

PULMONARY FIBROSIS IN A WIDE RANGE OF ILDs OR CTDs

ILD patient profiles

CTD-ILD patient profiles

Contact us for any questions or further information

References
  1. 1.

    Raghu G, Collard HR, Egan JJ, et al; on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.

  2. 2.

    Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of ... in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.

  3. 3.

    Theodore AC, Tseng C-H, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012;142(3): 614-621.

  4. 4.

    Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91(suppl 2):S3-S10.

  5. 5.

    Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146(2):422-436.

  6. 6.

    Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941-1952.

  7. 7.

    Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074.